New paper supports using Hevylite to monitor IgA myeloma patients
This 2015 publication by Dr Jerry Katzmann and colleagues from the Mayo Clinic concluded:
“HLC [Hevylite®] assays can be used to monitor IgA MM and provide similar information to the combination of SPEP, IFE, and total IgA quantification. Triaging of β-migrating IgA MM samples to IgA HLC assays should simplify monitoring of these patients.”
This study compared Hevylite® to electrophoresis assays and total immunoglobulin measurements for monitoring patients with these “difficult to measure“ IgA monoclonal proteins.
In IgA Multiple Myeloma (MM) post-treatment samples, Hevylite® detected monoclonality in 45% of samples compared to only 15% by SPE and 40% by abnormal total IgA.
The 97% sensitivity of Hevylite® in MM and MGUS indicates that almost all IgA MM patients can be monitored by HLC for both clonality and quantification.